Gestational trophoblastic disease

Berkowitz, Ross S.; Goldstein, Donald P.

doi:10.1002/1097-0142(19951115)76:10+<2079::aid-cncr2820761329>3.0.co;2-o

Cited by 63 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preferable remission rates have been reported for patients with nonmetastatic disease and for those with low-risk and mediumrisk metastatic disease [6,7]. Even in the high-risk group, combination chemotherapy with etoposide, MTX, actinomycin D, cyclophosphamide and vincristine has been shown to induce remission in about 70% of patients [8,9]. After the patients show negative hCG levels, additional chemotherapy must be administered to reduce the risk of a relapse, but no consensus has been achieved concerning the times of chemotherapy.…”

Section: Gestationalmentioning

confidence: 99%

Gonadotropin-Releasing Hormone-Induced Elevation of Serum hCG in Choriocarcinoma: A Case Report.

et al. 1998

View full text Add to dashboard Cite

Abstract. We evaluated the effect of GnRH on the serum hCG level in gestational trophoblastic disease (GTD). Five patients with GTD were studied. Three patients had hydatidiform mole (two complete and one partial mole) and two had choriocarcinoma. Blood samples were collected immediately before and 30, 60 min after the 100 µg GnRH iv injection, followed by hCG assay. Only one case of choriocarcinoma demonstrated an hCG increase after intravenous administration of GnRH (positive GnRH test). In that case, the hCG level dropped to the normal range after eight cycles of chemotherapy but the GnRH test was still positive, suggesting the existence of viable cancer cells. Since the GnRH test became negative, no increase in hCG has been observed, indicating that the patient achieved complete remission. Although a positive GnRH test is not common in GTD, GnRH test before treatment might be useful to find a positive case where the test can be repeated to determine complete remission and the time when the chemotherapy may be discontinued.

show abstract

Section: Gestationalmentioning

confidence: 99%

Gonadotropin-Releasing Hormone-Induced Elevation of Serum hCG in Choriocarcinoma: A Case Report.

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Gestational trophoblastic disease (GTD) is classified histopathologically as complete or partial mole, invasive mole, placental site trophoblastic tumour, and gestational choriocarcinoma (1). Menarche age, parity, first pregnancy age, mole pregnancy history, time interval between previous pregnancies, genetic factors, malnutrition, viral infections, and socioeconomic level all predispose to GTD (2).…”

Section: Introductionmentioning

confidence: 99%

Incidence of gestational trophoblastic disease in Tokat province, Turkey

Çakmak¹,

Toprak²,

Nacar³

et al. 2014

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

59,754 births in Tokat province. During this period, 73 cases were diagnosed as GTD histopathologically. The calculated GTD incidence was 1.22 per 1000 births. The mean age of the diagnosed patients was 28.6±7.3 (range 17-51) years. Many patients were aged 20-29 years (Figure 1). The mean numbers of pregnancies, births, and abortions were 3.5±2.9 (range 1-15), 1.3±1.4 (range 0-5), and 1.1±2.3 (range 0-13),Objective: This study investigated the incidence of gestational trophoblastic disease (GTD) in Tokat province, Turkey. Material and Methods:The medical records of patients who had been diagnosed and treated at one university hospital, six government hospitals, and one specialist hospital in Tokat province between January 2005 and December 2012 were evaluated retrospectively.Results: During the study period, there were 59,754 births and GTD was diagnosed in 73 cases. The calculated GTD incidence was 1.22/1000. The mean age of the patients diagnosed with GTD was 28.6±7.3 (range 17-51) years. In GTD, complete moles occurred in 26%, partial moles in 74%, and no invasive moles, choriocarcinomas, or placental site trophoblastic tumours were found. Only two patients received chemotherapy (methotrexate). There was no mortality associated with the disease during follow-up. Conclusion:The incidence of GTD in Tokat province was 1.2 per 1000 births. Early diagnosis, treatment, and follow-up play a critical role in preventing the morbidity and mortality associated with disease. The incidence of GTD, which has a high recovery rate with adequate treatment and follow-up, can be determined from regional and community-based research. (J Turk Ger Gynecol Assoc 2014; 15: 22-4) Key words: Gestational trophoblastic disease, molar pregnancy, incidence Received: 11 October, 2013 Accepted: 09 November, 2013 Incidence of gestational trophoblastic disease in Tokat province, Turkey

show abstract

“…Hydatidiform mole, a pathological condition, affects the course of a normal pregnancy 8 .Approximately 15-25% of moles developed into invasive moles, and 3-5% into a choriocarcinoma 9 . Gestational choriocarcinoma was preceded by hydatidiform mole in 30-60% of cases which was 1000 times greater than after a normal pregnancy.The presence of androgenetic cell lines, particularly in those with a purely androgenetic complete hydatidiform mole component, warrants follow up because of some risk of persistent gestational trophoblastic disease 10 .…”

Section: Introductionmentioning

confidence: 99%

Incidence and clinical outcome of Gestational Trophoblastic diseases in a tertiary care hospital

2017

Int. J. Curr. Res. Med. Sci.

View full text Add to dashboard Cite

Introduction: Gestational trophoblastic disease (GTD) consists of group of disorders having pathology of abnormal trophoblastic proliferation ranging from hydatidiform mole to gestational trophoblastic neoplasia. Based on differences in morphology, histopathology, karyotype and clinical features, hydatidiform mole can be categorized into partial and complete moles. Molar pregnancy incidence varies across countries. The incidence of molar pregnancy in Asia is 1:100-300, choriocarcinoma 1:1000-2000 of live born children. Aim: To determine the incidence, clinical outcome and management of women with gestational trophoblastic disease (GTD) at tertiary care hospital during a study period of 6 months. Materials and Methods: This is an observational descriptive study conducted over a period of 6 months. In our study, total 18 cases were diagnosed with GTD, based on ultrasound, biochemical and histological examination. Results: During study period, total patients delivered were 3610, out of which 18 cases had GTD. The overall incidence of GTD was 1/200 pregnancies, including cases of partial mole, complete mole, choriocarcinoma, and invasive mole. Highest incidence was found in extremes of age. 77.7% of cases presented in the first trimester, while 22.3% of cases presented in the second trimester. 77.7% of cases were complete mole, 11.1% were partial mole, and 11.1% were diagnosed as gestational trophoblastic neoplasm. Majority of cases (94.4%) presented with vaginal bleeding; pregnancy induced hypertension and preeclampsia was present in 16.6% of cases, 66.6% had abdominal cramps, 44.4% presented with signs of dehydration due to hyperemesis gravidarum, 22.2% had hyperthyroidism. Ultrasound was diagnostic in 95% cases, while histopathological examination was diagnostic in 100% of the cases. The incidence of GTDs in our hospital (1 in 200) is comparable to the incidence in Middle East and Far Eastern countries. Conclusion: In our study, we found a high incidence of GTD in primigravidas. Most patients who had been diagnosed with GTD on USG were in first trimester.

show abstract

Gestational trophoblastic disease

Cited by 63 publications

References 48 publications

Gonadotropin-Releasing Hormone-Induced Elevation of Serum hCG in Choriocarcinoma: A Case Report.

Gonadotropin-Releasing Hormone-Induced Elevation of Serum hCG in Choriocarcinoma: A Case Report.

Incidence of gestational trophoblastic disease in Tokat province, Turkey

Incidence and clinical outcome of Gestational Trophoblastic diseases in a tertiary care hospital

Contact Info

Product

Resources

About